Clinical trials: Stage II Adult Soft Tissue Sarcoma
Ovarian Cancer, Sarcoma
Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Conditions
- Ovarian Cancer, Sarcoma, Small Intestine Cancer
- Trial name
- NCT00004066
- Testing
- filgrastim, docetaxel, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Sarcoma
Irinotecan in Treating Patients With Stage IV or Recurrent Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients who have stage IV or…
- Trial name
- NCT00003719
- Testing
- irinotecan hydrochloride
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Ewing's Sarcoma
Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma
This research study is a Phase II clinical trial to test the efficacy of Olaparib in adult participants with recurrent/metastatic Ewing's Sarcoma following failure of prior chemotherapy.
- Trial name
- NCT01583543
- Testing
- Olaparib
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Massachusetts General Hospital
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00544115
- Testing
- busulfan, cyclophosphamide, cyclosporine
- Volunteers
- 260 people
- Sponsor
- City of Hope Medical Center
Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma
BMS-247550 in Treating Patients With Advanced Soft Tissue Sarcoma
Phase II trial to study the effectiveness of BMS-247550 in treating patients who have advanced soft tissue sarcoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
- Trial name
- NCT00022542
- Testing
- ixabepilone
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoma
Radiation Therapy and Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With High-Grade Lymphoma or Acute Lymphoblastic Leukemia
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00004898
- Testing
- filgrastim, cyclophosphamide, etoposide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Northwestern University
Glioblastomas, Gliosarcoma
Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed Glioblastoma
Standard treatment for glioblastomas includes radiation and chemotherapy with a drug called temozolomide (Temodar); however, glioblastomas frequently develop resistance to standard treatment and recur or progress.
- Trial name
- HBO (NCT00936052)
- Testing
- Hyperbaric Oxygen Therapy
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Neurological Surgery, P.C.
Stage III Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma
Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Primary or Recurrent Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Conditions
- Stage III Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage IVA Adult Soft Tissue Sarcoma, Stage IIB Adult Soft Tissue Sarcoma
- Trial name
- NCT00017160
- Testing
- doxorubicin, filgrastim, ifosfamide
- Where
- 235 sites in United States, Canada
- Sponsor
- Radiation Therapy Oncology Group
Stage I Adult Soft Tissue Sarcoma, Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity
EF5 to Evaluate Tumor Hypoxia in Patients With High-Grade Soft Tissue Sarcoma or Mouth Cancer
This laboratory study is using EF5 to evaluate tumor hypoxia in patients with high-grade soft tissue sarcoma or mouth cancer. Using the drug EF5 to measure the oxygen level in tumor cells may help in planning cancer treatment
- Conditions
- Stage I Adult Soft Tissue Sarcoma, Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage II Adult Soft Tissue Sarcoma, Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity
- Trial name
- NCT00896961
- Testing
- EF5, diagnostic laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Colorectal Cancer
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
This is a phase I/II, non randomized, open-label, dose escalation study to investigate the safety, tolerability and preliminary efficacy of CB-103.
- Conditions
- Breast Cancer, Colorectal Cancer, Adenoid Cystic Carcinoma, Non-hodgkin Lymphoma
- Trial name
- NCT03422679
- Testing
- CB-103
- Where
- 17 sites in United States, France and 4 more
- Volunteers
- 79 people
- Sponsor
- Cellestia Biotech AG
Sarcoma, Soft Tissue Sarcoma
Gemcitabine Plus Ascorbate for Sarcoma in Adults
This study will enroll patients who have a diagnosis of locally advanced, unresectable or metastatic soft tissue or bone sarcoma (except gastrointestinal stromal tumors and Kaposi's sarcoma) from any site.
- Conditions
- Sarcoma, Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma, Metastatic Bone Tumor
- Trial name
- NCT03468075
- Testing
- Ascorbate, Gemcitabine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Mohammed Milhem, MBBS
Bladder Cancer, Breast Cancer
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Conditions
- Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer
- Trial name
- NCT00014456
- Testing
- filgrastim, docetaxel, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Chronic Myeloproliferative Disorders, Kidney Cancer
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant using stem cells that closely match the patient's stem cells, helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00295997
- Testing
- anti-thymocyte globulin, filgrastim, graft-versus-tumor induction therapy
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- University of California, San Francisco
Chronic Myeloproliferative Disorders, Leukemia
Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy, such as busulfan and fludarabine, before a donor stem cell transplant helps stop the growth of cancer and abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00448201
- Testing
- anti-thymocyte globulin, sargramostim, therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Colorectal Cancer Not MSI-H or MMR-deficient, GIST
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
Assessment of the efficacy and safety of Regorafenib and Avelumab in patients with advanced or metastatic solid tumors (ten cohorts), once the Recommanded Phase II Dose (RP2D) has been determined (phase I trial).
- Conditions
- Colorectal Cancer Not MSI-H or MMR-deficient, GIST, Oesophageal or Gastric Carcinoma, Biliary Tract Cancer
- Trial name
- REGOMUNE (NCT03475953)
- Testing
- Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib
- Where
- 7 sites in France
- Volunteers
- 747 people
- Sponsor
- Institut Bergonié
Gastrointestinal Stromal Tumor, Sarcoma
SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue Sarcomas
Phase II trial to study the effectiveness of SU5416 in treating patients who have advanced, metastatic, or recurrent soft tissue sarcomas. SU5416 may stop the growth of soft tissue sarcomas by stopping blood flow to the tumor.
- Trial name
- NCT00005862
- Testing
- semaxanib
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma
Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00822848
- Testing
- epirubicin hydrochloride, ifosfamide, sorafenib tosylate
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- OHSU Knight Cancer Institute
Langerhans Cell Histiocytosis (LCH), Histiocytoses Erdheim-chester Disease
Lenalidomide for Adult Histiocyte Disorders
This research study is studying a chemotherapy drug Lenalidomide as a possible treatment for one of three histiocyte disorders: Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD), or histiocytic sarcoma (HS).
- Conditions
- Langerhans Cell Histiocytosis (LCH), Histiocytoses Erdheim-chester Disease, Histiocytic Sarcoma (HS)
- Trial name
- NCT02523040
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Dana-Farber Cancer Institute
Kaposi Sarcoma
Propranolol for the Treatment of Kaposi Sarcoma in Adults
Kaposi sarcoma (KS) lesions are initiated by endothelial cells infected with KS herpesvirus (KSHV), also known as human herpesvirus 8 (HHV-8).
- Trial name
- NCT06445166
- Testing
- Propranolol Hydrochloride
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Washington University School of Medicine
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Umbilical cord blood transplantation may be able to replace cells destroyed by chemotherapy.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00054236
- Testing
- anti-thymocyte globulin, filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Case Comprehensive Cancer Center